GEA was awarded for best manufacturing technology and equipment at the CPhI Pharma Awards, which took place this week during the leading trade fair CPhI Worldwide in Barcelona, Spain.
As a frontrunner in the design and supply of state of the art manufacturing solutions for both solid and liquid dosage forms, GEA won the Award “Excellence in Pharma: Manufacturing Technology and Equipment” for their ConsiGma™ continuous processing platform.
The ConsiGma™ continuous tableting line is a multipurpose platform that has been designed to transfer powder into coated tablets in development, pilot, clinical and production facilities in a single compact unit. The system can perform dosing and mixing of raw materials, wet or dry granulation, drying, tableting, coating and quality control, all in one integrated solution.
“For us, continuous manufacturing (CM) is fundamental to the future of the pharmaceutical industry, CM represents an exciting step forward in drug production,” said Marcus Michel, Executive Vice President of GEA’s Pharma business. “That ConsiGma™ has been recognized by a panel of industry peers reflects and reinforces GEA’s philosophy of implementing CM systems, particularly for high value products. We thank the judges for their considered appraisal of our technology, which is important for both our company and our customers, and the team behind our ConsiGma™ portfolio. We feel that CPhI is an excellent environment to present our advanced manufacturing solutions and enhance our clients’ ability to develop and create high quality products,” he added.
“To receive this award amongst a number of very strong contenders is an incredible result and underpins the industry trend of implementing CM solutions. It’s a milestone in the production of OSDs (Oral Solid Dosage) and truly represents the future of pharma manufacturing,” concluded Marcus Michel.
It’s thanks to GEA’s ConsiGma™ that, in 2015, Vertex Pharmaceuticals became the first pharma company to receive FDA approval for a therapeutic that was both developed and commercially manufactured using a CM platform. And GEA’s ConsiGma™ 25 unit forms the basis of a groundbreaking – also award-winning – collaboration between Pfizer, GSK and G-CON to develop the next generation of portable, continuous, miniature and modular (PCMM) solutions for pharma production. These on-demand mini-factories can be set up to manufacture medicines at any production scale, anywhere in the world where basic facilities are available. GEA is convinced that ConsiGma™ will revolutionize the way that tablets are produced.
